News | November 15, 2023
JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ
European operations' revenue grew 58.4% to Rs 599.7 crore
US business grew by +12.8% YoY
The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore vs. Rs. 409 crore in Q2FY23
We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
Subscribe To Our Newsletter & Stay Updated
